336 related articles for article (PubMed ID: 20353397)
1. Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.
Chapman R; Chege G; Shephard E; Stutz H; Williamson AL
Curr HIV Res; 2010 Jun; 8(4):282-98. PubMed ID: 20353397
[TBL] [Abstract][Full Text] [Related]
2. Preclinical development of BCG.HIVA
Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
Rosario M; Fulkerson J; Soneji S; Parker J; Im EJ; Borthwick N; Bridgeman A; Bourne C; Joseph J; Sadoff JC; Hanke T
J Virol; 2010 Aug; 84(15):7815-21. PubMed ID: 20484495
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.
Saubi N; Mbewe-Mvula A; Gea-Mallorqui E; Rosario M; Gatell JM; Hanke T; Joseph J
PLoS One; 2012; 7(8):e42559. PubMed ID: 22927933
[TBL] [Abstract][Full Text] [Related]
6. Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned.
Kilpeläinen A; Maya-Hoyos M; Saubí N; Soto CY; Joseph Munne J
Expert Rev Vaccines; 2018 Nov; 17(11):1005-1020. PubMed ID: 30300040
[TBL] [Abstract][Full Text] [Related]
7. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine.
Chujoh Y; Matsuo K; Yoshizaki H; Nakasatomi T; Someya K; Okamoto Y; Naganawa S; Haga S; Yoshikura H; Yamazaki A; Yamazaki S; Honda M
Vaccine; 2001 Dec; 20(5-6):797-804. PubMed ID: 11738743
[TBL] [Abstract][Full Text] [Related]
8. [The application of recombinant Bacillus Calmette-Guérin vaccine and its vector in infectious disease].
Zulpiya T; Ding J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Oct; 30(5):1136-40. PubMed ID: 24459985
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of recombinant bacille Calmette-Guérin in inducing humoral and cell mediated immunities against human immunodeficiency virus type 1 third variable domain in immunized mice.
Kim YJ
Yonsei Med J; 2011 Jan; 52(1):173-80. PubMed ID: 21155051
[TBL] [Abstract][Full Text] [Related]
10. Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.
Kilpeläinen A; Saubi N; Guitart N; Moyo N; Wee EG; Ravi K; Hanke T; Joseph J
Front Immunol; 2019; 10():923. PubMed ID: 31156614
[TBL] [Abstract][Full Text] [Related]
11. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines.
Aldovini A; Young RA
Nature; 1991 Jun; 351(6326):479-82. PubMed ID: 2046750
[TBL] [Abstract][Full Text] [Related]
12. Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routes.
Saubi N; Im EJ; Fernández-Lloris R; Gil O; Cardona PJ; Gatell JM; Hanke T; Joseph J
Clin Dev Immunol; 2011; 2011():516219. PubMed ID: 21603216
[TBL] [Abstract][Full Text] [Related]
13. Development of BCG as a live recombinant vector system: potential use as an HIV vaccine.
Fuerst TR; Stover CK; de la Cruz VF
Biotechnol Ther; 1991; 2(1-2):159-78. PubMed ID: 1845119
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of cell-mediated immune response in mice by whole HIV-1 gag in Mycobacterium bovis BCG as a live vaccine candidate.
Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Sutthent R; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):113-22. PubMed ID: 19323043
[TBL] [Abstract][Full Text] [Related]
15. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
16. Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors.
Hopkins R; Bridgeman A; Bourne C; Mbewe-Mvula A; Sadoff JC; Both GW; Joseph J; Fulkerson J; Hanke T
Eur J Immunol; 2011 Dec; 41(12):3542-52. PubMed ID: 21932450
[TBL] [Abstract][Full Text] [Related]
17. Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.
Joseph J; Saubi N; Pezzat E; Gatell JM
Expert Rev Vaccines; 2006 Dec; 5(6):827-38. PubMed ID: 17184220
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant.
Sun J; Hou J; Li D; Liu Y; Hu N; Hao Y; Fu J; Hu Y; Shao Y
Vaccine; 2013 Jan; 31(3):472-9. PubMed ID: 23174201
[TBL] [Abstract][Full Text] [Related]
19. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
20. CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts.
Kato S; Shida H; Okamura T; Zhang X; Miura T; Mukai T; Inoue M; Shu T; Naruse TK; Kimura A; Yasutomi Y; Matsuo K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33087465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
